Victrex plc (LON:VCT) Insider Urmi Prasad Richardson Buys 100 Shares

Posted by Editorial Team on Mar 25th, 2025

Victrex plc (LON:VCT – Get Free Report) insider Urmi Prasad Richardson bought 100 shares of the business’s stock in a transaction on Friday, March 21st. The shares were acquired at an average cost of GBX 958 ($12.38) per share, with a total value of £958 ($1,237.89).

Victrex Stock Down 2.5 %

Victrex stock opened at GBX 925 ($11.95) on Tuesday. The company has a market capitalization of £806.90 million, a PE ratio of 26.28, a price-to-earnings-growth ratio of 1.92 and a beta of 0.69. The company has a debt-to-equity ratio of 10.93, a quick ratio of 1.99 and a current ratio of 4.39. Victrex plc has a fifty-two week low of GBX 816 ($10.54) and a fifty-two week high of GBX 1,368 ($17.68). The firm has a 50 day moving average price of GBX 979.48 and a 200 day moving average price of GBX 965.74.

Victrex (LON:VCT – Get Free Report) last issued its quarterly earnings data on Tuesday, December 24th. The company reported GBX 51.70 ($0.67) earnings per share for the quarter. Victrex had a return on equity of 6.67% and a net margin of 10.81%. Research analysts expect that Victrex plc will post 73.1078905 earnings per share for the current year.

Victrex Increases Dividend

The company also recently announced a dividend, which was paid on Friday, February 21st. Shareholders of record on Thursday, January 23rd were given a GBX 46.14 ($0.60) dividend. This is an increase from Victrex’s previous dividend of $13.42. This represents a yield of 5.26%. The ex-dividend date of this dividend was Thursday, January 23rd. Victrex’s payout ratio is currently 170.47%.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank decreased their target price on shares of Victrex from GBX 1,290 ($16.67) to GBX 1,170 ($15.12) and set a “hold” rating on the stock in a research report on Wednesday, December 4th.

Read Our Latest Stock Report on Victrex

Victrex Company Profile

(Get Free Report)

Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.